Streetbeat News

XTLB

XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

Industry

Biotechnology

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Open

1.67

Mkt cap

23M

Volume

5.1K

High

1.83

P/E Ratio

-61.00

52-wk high

4.99

Low

1.67

Div yield

N/A

52-wk low

0.76

U.S. stocks rose after the Federal Reserve left interest rates unchanged, with the Dow, NASDAQ, and S&P 500 all posting gains. Industrials and health care sectors saw mixed performance. Several companies experienced significant stock movements, including ETAO International, XTL Biopharmaceuticals, and TruGolf Holdings seeing sharp increases, while Lifecore Biomedical, Aquestive Therapeutics, and Signet Jewelers reported declines. The Fed's decision to maintain rates between 5.25% and 5.5% was anticipated, aligning with investor expectations.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 7:22 pm

Lifecore Biomedical's shares plummeted by 31.7% after announcing the conclusion of its strategic evaluation process, management changes, and board reshuffling. Other stocks experienced significant movements, with gainers like ETAO International and XTL Biopharmaceuticals seeing sharp increases due to a reverse stock split and acquisition news, respectively. Losers included NuScale Power Corporation, which dropped 28% following a downgrade by Wells Fargo, and Ontrak, Inc., which fell 26% after a previous day's surge.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 6:03 pm

Healthcare stocks experienced significant movements in Wednesday's intraday session. XTL Biopharmaceuticals led the gainers with a 95.8% increase, while Lifecore Biomedical topped the losers, declining by 31.4%. Other notable movers include Etao International, Annovis Bio, and Taysha Gene Therapies, which reported Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 5:31 pm

XTL Biopharmaceuticals' shares surged following the announcement of a binding term sheet to acquire all shares of Social Proxy. This strategic move could potentially expand XTL Biopharmaceuticals' portfolio and market presence.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 5:29 pm

U.S. stocks were mostly flat as markets awaited the Federal Reserve's interest rate decision. Industrials shares rose by 0.5%, while energy shares fell by 0.6%. Crude oil inventories in the U.S. declined, contrary to market expectations. ETAO International announced a reverse stock split, XTL Biopharmaceuticals plans to acquire The Social Proxy, and TruGolf Holdings expanded its AI technology licensing agreement. Lifecore Biomedical concluded its strategic evaluation, Aquestive Therapeutics priced a public offering, and Signet Jewelers reported disappointing sales and guidance.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 4:47 pm

U.S. stocks edged lower ahead of the Federal Reserve's interest rate decision, with the Dow, NASDAQ, and S&P 500 all seeing slight declines. General Mills reported better-than-expected Q4 financial results, with a slight sales decline but beating analyst estimates. Utilities shares rose, while energy shares fell. Several companies saw significant stock movements, including ETAO International, XTL Biopharmaceuticals, and TruGolf Holdings experiencing sharp increases, whereas Lifecore Biomedical, NuScale Power Corporation, and Momentus Inc. saw notable declines.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 2:53 pm

XTL Biopharmaceuticals (XTLB) is set to acquire The Social Proxy, obtaining all issued and outstanding share capital, initially representing 44.6% of the share capital, with a payment of $430,000 to Social Proxy shareholders. This acquisition expands XTLB's IP portfolio into AI web data, as The Social Proxy is an AI company focused on developing a platform for AI & BI applications. Additionally, The Social Proxy has secured $1.5 million in a private placement.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 2:23 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Notably, Applied DNA Sciences (APDN) surged by 33.1%, while Titan Pharma (TTNP) dropped by 18.2%. Other gainers include XTL Biopharmaceuticals (XTLB), 2seventy bio (TSVT), DBV Technologies (DBVT), Elicio Therapeutics (ELTX), and Moleculin Biotech (MBRX). Losers also featured Biophytis (BPTS), Molecular Templates (MTEM), Nanobiotix (NBTX), TC BioPharm (TCBP), and Trxade Health (MEDS).

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 1:06 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Comera Life Sciences (CMRA), SenesTech (SNES), Aravive (ARAV), China SXT Pharmaceuticals (SXTC), Co-Diagnostics (CODX), and Oncternal Therapeutics (ONCT) saw gains following their Q3 earnings reports. Conversely, XTL Biopharmaceuticals (XTLB), NeuroMetrix (NURO), TRACON Pharma (TCON), Jaguar Health (JAGX), Intelligent Bio Solutions (INBS), and Sunshine Biopharma (SBFM) experienced declines. The movements were attributed to recent earnings reports and trading volumes.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 9:31 pm

XTL Biopharmaceuticals has received a notification from Nasdaq regarding a minimum bid price deficiency. The company's shares have been trading below the minimum $1.00 per share requirement for continued listing.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 8:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.